Targeting the GDF15 Signalling for Obesity Treatment: Recent Advances and Emerging Challenges

Jincheng Zhang1,2,3, Jingquan Sun2, Jielang Li1

  • 1Division of Abdominal Tumor Multimodality Treatment, Department of Medical Oncology, Cancer Center and National Clinical Research Center for Geriatrics and Laboratory of Molecular Targeted Therapy in Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.

Insights

The GDF15-GFRAL pathway regulates metabolism and body weight. Targeting this pathway offers a promising obesity treatment strategy with minimal impact on muscle mass.

Area of Science:

  • Metabolic research
  • Obesity research
  • Endocrinology

Background:

  • Obesity is a global health crisis requiring novel treatments.
  • The Growth Differentiation Factor 15 (GDF15)-Glial cell-derived neurotrophic factor family receptor alpha-like (GFRAL) pathway is integral to metabolic regulation.
  • Preserving skeletal muscle mass during weight loss is critical.

Purpose of the Study:

  • To review the regulation, distribution, and metabolic roles of the GDF15-GFRAL axis.
  • To explore the potential of targeting the GDF15-GFRAL pathway for obesity treatment.
  • To discuss recent advancements and challenges in GDF15-GFRAL-targeted obesity therapies.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of GDF15-GFRAL pathway mechanisms.
  • Exploration of therapeutic strategies targeting the GDF15-GFRAL axis.

Main Results:

  • The GDF15-GFRAL pathway significantly influences appetite and body weight.
  • Targeting this pathway shows promise for obesity treatment.
  • This approach may preserve skeletal muscle mass during weight reduction.

Conclusions:

  • The GDF15-GFRAL axis is a key regulator of energy homeostasis.
  • Targeting the GDF15-GFRAL pathway presents a viable strategy for combating obesity.
  • Further research is needed to overcome challenges in clinical application.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Hormonal Regulation01:40

Hormonal Regulation

Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.1K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.3K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
374
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K